Onconetix Inc. will acquire all issued and outstanding equity interests of Realbotix LLC in exchange for newly issued shares of Onconetix common stock. Following the completion of the transaction, expected in the second half of 2026, Realbotix Parent will own between 75% and 90% of the fully diluted shares of the combined company, depending on Onconetix’s cash position at closing. Andrew Kiguel, current CEO of Realbotix Corp, will become CEO of the combined company. Realbotix, recognized for its AI-powered humanoid robotics and enterprise partnerships with companies like Ericsson, will bring its portfolio and technological advancements to the newly combined entity, which is anticipated to trade on Nasdaq. The boards of both companies have unanimously approved the transaction, which remains subject to customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653686-en) on February 12, 2026, and is solely responsible for the information contained therein.